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Objectives: Intravascular lithotripsy (IVL) clinical efficacy and safety in the treatment of calcified 
coronary artery disease (CAC) is not well known. We sought to assess IVL safety and efficacy in CAC. 
Methods: A comprehensive online databases search were performed to identify intravascular lithotripsy 
studies in patients with coronary artery disease. The primary outcome was IVL related change in the 
mean pre and post-procedural diameter of the coronary artery.  
Results: A total of 4 studies with 282 patients were included. The mean pre-IVL coronary diameter for all 
patients was 1.01mm, while the mean post-IVL coronary diameter was 2.70mm. The mean pre-post IVL 
diameter difference of coronary arteries on the pooled analysis was significantly lower by 4.08 mm (95% 
CI -4.94 to -3.30, p≤0.00001). The Overall increase in the post-IVL lumen diameter was significantly 
higher than the pre-IVL diameter with a mean difference of -4.16 (95% CI -5.08 to -3.24, p=0.000001). 
However, compared to pre-IVL, there was a significant reduction in the overall mean difference of 
luminal calcium angle after IVL of the stented coronary arteries (0.09, 95% CI 0.002-0.16, p=0.01).  
Conclusion: Intravascular lithotripsy can offer a significant improvement in the vessel lumen to facilitate 
coronary stent delivery and deployments in severely calcified coronary arteries.  
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Article highlights: 
• Intravascular lithotripsy can yield significant lumen gain of up to 4.16mm by disrupting the 
calcium in the media and intima coronary arteries. 
• IVL has the best yield in severe CAC with stenosis >50%, and calcium angle >270 degrees as seen 
on intravascular imaging, facilitating stent delivery and preventing coronary recoil. 
• Intra-coronary imaging helps characterize and evaluate coronary calcification and guide IVL 












About 20% of the patients undergoing Percutaneous Coronary Intervention (PCI) have treatment failure 
secondary to severe coronary artery calcification (CAC). CAC is an independent factor that reduces the 
likelihood of successful PCI by expanding drug-eluting stents (DES) [1, 2].  
Several techniques are frequently employed to facilitate calcium fracture in patients with CAC, including 
high-pressure non-compliant balloons, cutting balloons, excimer lasers, rotational and orbital 
atherectomy devices [3]. However, these techniques are associated with increased risk of complications 
or may risk stent disruption when PCI has already been performed with under expansion of stent [4] 
Coronary intravascular lithotripsy (IVL) has been recently developed in order to manage CAC. The 
concept of IVL is similar to lithotripsy used in nephrolithiasis. IVL delivers circumferential, unfocused, 
and pulsatile energy to safely disrupt calcium within the target lesion. The purpose is to fracture the 
calcified plaque to gain enough lumen diameter to pass and deploy the DES [5] successfully.  
IVL has been shown to offer better safety, given the minimal vascular approach and lower procedure-
related complications. The ultrasonic waves travel through a balloon-based small size catheter 
disrupting only the superficial and deep calcium deposits with limited risk of vascular rupture or 
dissection [6].  
Given the limited data in the efficacy and safety of IVL, we aimed in this systematic review to review the 
literature on the efficacy and safety of IVL in terms of coronary vessel dilatation. 
2. Methods: 
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) statement (Figure 1)  
2.1 Eligibility criteria 
Studies were included if they met all the following inclusion criteria: 1) studies that evaluated coronary 
shock wave intravascular lithotripsy, 2) studies of patients with the right and left coronary circulation 
calcified disease. For inclusion, the studies had to report data that evaluated the effectiveness of 
shockwave intravascular lithotripsy for left coronary circulation with baseline pre and post-procedural 
changes in vessel diameter. The studies also had to report data on shockwave intravascular lithotripsy 
effectiveness for left coronary circulation with baseline pre and post-procedural changes in vessel 
diameter. 
2.2 Search strategy:  
A literature search of PubMed, EMBASE, Cochrane Central, and ClinicalTrials.gov databases were 











September 2020. The search items include medical subject headings (MeSH) and keywords: 
“intravascular shockwave lithotripsy,” “coronary lithotripsy,” “IVL,” “S-IVL,” “acute coronary syndrome,” 
“ST-elevation myocardial infarction,” “non-ST elevation myocardial infarction,”  “unstable angina,” 
“stable angina,” “calcified coronary artery disease,”  “ failed percutaneous coronary intervention,” 
“stent under expansion,” “drug-eluting stent,” and “failed rotational atherectomy.”  These terms were 
combined using Boolean operators (“AND” or “OR”), and final results from all the possible combinations 
were downloaded into an EndNote library. Additional studies were identified by reviewing the reference 
lists of potentially relevant studies. The full search strategy is shown in the PRISMA diagram (Figure 1) 
and Supplemental file 1.  
2.3 Study Selection: 
All studies, including any available clinical trials or observational studies, were evaluated. Two authors 
(Y.S and S.B) independently reviewed the search results for studies that met the eligibility criteria. 
Uncertainty regarding study inclusion was resolved by consensus with a third author (W.U). The first 
phase of screening involved screening of titles and abstracts meeting inclusion criteria. The second 
phase of screening required full-text reading of articles that enable identifying items for data extraction 
based on the inclusion criteria. Irrelevant articles at this stage were excluded with reasons, as shown in 
Figure 1.   
2.4 Data collection and statistical analysis 
Statistical analysis was performed using the Cochrane Review Manager (RevMan) version 5.3. Data from 
each study that met the inclusion criteria were extracted into a table. The table's data elements included 
the country of the study, age of participants, sex of participants, sample size, comorbidities of 
participants, procedural parameters, safety, and follow-up. A random-effects model (inverse variance) 
was used to calculate the pooled mean difference and SD for luminal diameter change with a probability 
value of p<0.05 considered to be statistically significant. The “test for overall effect” was reported as z 
value corroborating the 95% confidence interval's inference. Higgins I-squared (I2) was determined as a 
measure of statistical heterogeneity where values of ≤ 50% corresponded to low to moderate 
heterogeneity while values ≥75% indicated high heterogeneity. The publication bias was depicted 
graphically and numerically as a forest plot, and Egger’s Regression Equation (ERE). The quality 
assessment of the included articles was performed using the Cochrane guidelines for the systematic 
review and meta-analysis, and Newcastle–Ottawa scale (NOS) where each study was screened for five 
different types of bias (selection, performance, detection, attrition, and reporting bias). The NOS scale 











3 Results:  
3.1 Search Results and Study Characteristics: 
Our search identified 2901 articles. Following duplicate (n=147) removal and irrelevant items (n=2684), 
70 articles were reviewed in full-text form. Based on the selection criteria, 4 articles qualified for final 
analysis consisting of two prospective, multicenter, single-arm, and interventional studies [9-12]. The 
detailed PRISMA flow diagram is shown in Figure 1. 
A total of 282 patients from 4 studies were included in our review. The baseline demographic 
characteristics, comorbidities, and procedural characteristics are shown in Table 1. The mean age of the 
population was 70 years. The baseline comorbidities of the population are shown in table 1. A total of 
severely calcified lesions (n=216, 71 %) were treated with IVL, where all the population included had 
severe coronary artery calcification and underwent an IVL procedure. The procedural characteristics 
include mean value: Balloon size (4.0 x 12mm), Balloon pressure (6atm), Catheter size (6fr).  
3.2 Pooled Analysis: 
The pooled analysis of the included studies is shown in Figure 5. The overall mean lumen gain after IVL 
of severely calcified vessels was 4.08mm (95% CI -4.94 to -3.30, p≤0.00001). (Figure 2) The 
heterogeneity among the included studies' outcomes was significantly higher with an I2=86% (p≤0.0001). 
(Figure 2A) The Disrupt CAD II study contributed more than one-third of the total population.  A 
sensitivity analysis was performed by excluding the study by Brinton et al. and showed heterogeneity of 
0%. (Figure 2B) The high heterogeneity by including Brinton et al. can be explained by under-reporting of 
IVL pre and post lumen area due to the absence of optical coherence tomographic view of vessels to 
measure lumen area.9 However, under the random-effects model's assumption, the distributed weight 
to estimate the summary effect size was comparable among all four studies (22.4% to 27.8%).  
The overall increase in the post-IVL lumen diameter was significantly higher than the pre-IVL diameter. 
The mean difference observed was -4.16 (95% CI -5.08 to -3.24, p=0.000001) (Figure 3). The 
heterogeneity among the outcomes of the included studies was moderate I2=70% (p=0.07). There was a 
significant reduction in the overall mean difference of luminal calcium angle after IVL (0.09, 95% CI 
0.002-0.16, p=0.01). There was no heterogeneity recorded in the included studies (I2=0%). (Figure 6) 
The overall increase in the post-IVL lumen diameter after coronary stenting was also significantly higher 
than the pre-IVL diameter. The mean difference observed was -2.17 (95% CI -2.70 to -1.63, p=0.000001) 
(Figure 3). However, compared to pre-IVL, there was a significant reduction in the overall mean 
difference of luminal calcium angle after IVL of the stented coronary arteries (0.09, 95% CI 0.002-0.16, 











MACCE and individual components of MACCE during in-hospital, 30-days, and 6-month follow-up, is 
shown in figure 4. The heterogeneity among the included studies' outcomes was none to minimal 
I2=0%-I2=37% (p=0.36, p=0.22), respectively (Figure 3). 
3.3 Quality of Included Studies: 
The included studies' methodological quality was moderate based on the mean New Castle Ottawa Scale 
(NOS) score of 6. The retrospective nature of the study's randomization could not be achieved; this 
raised concern for selection bias. However, the included population was matched based on their 
demographic and baseline characteristics, minimizing this risk. The risk of attrition bias was reduced by 
adaptation of intention to treat model. Due to the index procedure's interventional nature, and the 
study's single-arm design, the risk of performance bias could not be determined. Similarly, an accurate 
assessment of the detection bias risk was limited. Although one can speculate a high risk of detection 
bias based on the fact that investigators and patients were unblinded, the risk was minimal, due to the 
objective angiographic assessment of the effect size. The risk of reporting bias was minimal due to 
adequate reporting of outcomes. The detailed NOS is given in Table 2. The detailed bias summary and 
assessment are shown in Figure 5 and Figure 6. 
3.4 Publication Bias:  
The plot's vertical axis used standard error to estimate the sample size of the study, plotting large 
population studies on top and smaller at the bottom. The horizontal spread reflected the power and 
effect size of the included studies. Our funnel plot was not symmetrical on visual assessment, indicating 
that the limited scatter might be due to publication bias. (Figure 7) The numerical assessment of 
publication bias was done using Egger’s regression model that failed to show any publication bias or 
small study effects (ERE ≈ p=0.771). Furthermore, the heterogeneity among the outcomes of the 
included studies was self-explicable. First, as per the Cochrane handbook of the systematic review and 
meta-analysis, if the total count of included studies is less than ten, it is not possible to differentiate 
between true heterogeneity and findings merely by chance. Second, while all the studies unanimously 
supported the IVL, the high percentage of variability could be explained by the sampling error. 
4. Discussion:  
Our study is the first systematic review and meta-analysis to statistically pool the evidence for the use of 
IVL for the left coronary calcific disease. The pooled results of the four included studies suggest that IVL 
can get a luminal gain by 4.12mm with the success of implanting an eluting drug stent (DES). The overall 
post IVL lumen diameter was significantly higher than the pre-IVL diameter with a significant reduction 











is relatively safe procedure with very limited complication given in hospital MACCE (total n=11; 
Dissection type B=4; MI=7), 30-day MACCE (total n=16; cardiac mortality=1; MI=8; Dissection type B=4; 
Stent thrombosis=2, Target vessel revascularization(TVR)=1), and 6 months MACCE (total n=8; cardiac 
death=3; MI=5) 
Left calcified coronary disease can increase complications along with stent under expansion, which 
increases the risk of stent thrombosis, and higher MACCE. Calcium debulking procedures have 
traditionally been the first-line approach for left CAC disease to either deploy DES or to revascularize the 
affected vessel. These techniques debulk the superficial calcium, but occasionally at the cost of causing 
high intimal hyperplasia leading to early restenosis and distal embolization [7, 8]. Furthermore, acute 
coronary syndromes, including ST-elevation myocardial infarction (STEMI) and non-ST elevation 
myocardial infarction (NSTEMI), are not likely to undergo rotational atherectomy [7]. Coronary IVL, as a 
contemporary intervention, bears a better safety profile and potentially similar efficacy. It uses 
ultrasonic waves without any burr holes to target both superficial and deep layers of calcifications. 
Owing to the low-pressure balloon inflation with a small guided catheter, IVL is preferred over prior 
calcium debulking technique due to less vascular intimal hyperplasia, limiting restenosis of a vessel and 
longer patency.  
Our meta-analysis demonstrates that IVL independently can significantly reduce the calcium burden of 
the left coronary vessel. Of the included studies, DISRUPT CAD I by Brinton et al. was the first study to 
look at the efficacy of IVL [9]. A total of 60 patients were enrolled from seven different hospitals in five 
countries. The included study population had ≥1 lesion requiring PCI with heavy calcification, diameter 
stenosis ≥50%, and lesion length ≤32 mm. The primary outcome of the study was to assess clinical 
efficacy: the ability to reduce mean diameter stenosis <50% with no evidence of MACCE at 30 days 
follow-up. The results of DISRUPT CAD I showed a mean decrease of calcium angle, calcium thickness, 
lumen area was 23 º, 0.02 ± 0.01 mm, and 4.23 ± 2.33 mm, respectively. The calcium fracture was 
achieved in >25% of the lesions with a mean acute diameter gain of 2.1mm. The study resulted in 
favorable outcomes to deploy stents in up to 95% of patients who underwent IVL.  Ali et al. performed a 
subgroup analysis of the DISRUPT CAD I to study plaque properties and complications of IVL using 
optical coherence tomography (OCT). Ali et al. included 31 patients in subgroup analysis that underwent 
IVL and resulted that calcium fracture was highest in heavily calcified lesions (highest vs. lowest 
percentile of calcium: 77.8 % vs. 22.2 %, p=0.057). The mean acute luminal after IVL was 2.1 mm2, which 











dissection, as part of the  IVL procedure, was seen in 13% of the cases. The included population had no 
incidence of vessel perforation, slow flow/no reflow, and closure after IVL procedure [10].  
Recently, a large prospective study, DISRUPT CAD II by the same authors (ALI et al. [11]), assessed the 
efficacy of IVL in severely calcified lesions. The primary outcome of the study was MACCE (target vessel 
revascularization, myocardial infarction, and cardiac mortality) after IVL. This study reported a mean 
drop in calcium angle, calcium thickness, lumen area by 51º, 0.04 ±0.2 mm, and 4.83 ± 3.04mm, 
respectively. The post IVL acute luminal gain was 0.83 ± 0.47mm that increased to 7.7 ± 7.1% by DES 
implantation with residual stenosis of 32.7± 10.4%. IVL associated MACCE developed in 7 (5.8%) patients 
with non-Q wave myocardial infarction. The assessment of the rest of the complication review at 30 
days follow up showed no perforation, dissection, or early in-stent stenosis. The most recent study 
performed by Aksoy et al. in 2019 reported better results with IVL. He reported an improvement in 
stenosis from a baseline of 71.8±13.1% to 45.1 ±17.4% after IVL and 17.5±15.2% after stenting [12]. 
Luminal diameter improvement from 1.01±0.49mm to 1.90±0.61 with IVL and 2.88±0.56 mm after 
stenting. An 84.6% success rate has been reported in patients who had IVL as their primary procedure.  
Another study named IntravaScular lithotripsy for the Management of undILatable coronary stEnt: 
(SMILE) by Lelasi et al.[13] published in May 2020, access the safety of IVL in a calcified disease that 
present as in-stent restenosis, the study reported that IVL was a success in 87.1% of cases with 
significant improvement in minimal stent diameter ( pre IVL 0.81 mm; post IVL 3.23 mm; p=0.00001) and 
minimal stent cross-sectional area (pre IVL 3.35mm; post-IVL 7.61mm; p=0.00001). The study also 
reported only 1 case of non-fatal STEMI that occurred during periprocedural timing due to IVL balloon 
rupture, and there was no case of TVR, cardiac mortality, and stent thrombosis. In addition, Similarly, 
Wong et al., in his case series of 3 patients, reported reasonable success rates without any complications 
[14].  In terms of complications, MACCE reported in most studies is a combination of cardiac death, TVR, 
MI, and coronary artery dissection. The complications of IVL are most commonly due to balloon inflation 
of balloon rupture. We found MI as the most common complication after IVL at in-hospital, 30 days and 
six months follow up. The coronary artery dissection type B is the second most common complication 
after IVL. 
The major limitation of all studies was a small sample size and non-randomized control groups. Our 
meta-analysis pooled all studies to get a slightly larger sample size in order to see the more substantial 
evidence in favor of IVL. The 30-day and 6-month outcomes from available data show the capacity of 











injury and lower MACCE. Our study also highlights the paucity of clinical studies and the need for further 
controlled studies on longer follow-up duration. 
Recently initiated trials around the efficacy of IVL include DISRUPT CAD III (NCT03595176): a multicenter 
prospective study to evaluate the safety and effectiveness of the IVL procedure. In this study, 
approximately 392 subjects will be enrolled at 50 different sites. A minimum of half of the study 
population will be enrolled in the United States. A follow-up will be at discharge, 30 days, 6, 12, and 24 
months. DISRUPT CAD IV (NCT04151628): is a prospective single-arm study that would enroll 72 patients 
from Japan. Subjects will be followed at discharge, 30 days, 6,12, and 24 months. Another ongoing 
study, RAINBOW (NCT04013906) trial, a randomized clinical trial to evaluate the plaque modification 
after rotational atherectomy vs. IVL before DES implantation. 
6. Limitations: 
Due to the sparse data, only observational studies were involved; more studies, including randomized, 
double-blind studies, should be performed in the future to review the efficacy and to compare the 
complications of IVL. The included studies were single-arm with no comparison to other calcium 
debulking techniques, including atherectomy. We didn’t include SMILE registry results in our study given 
the data available in medians and no availability of standard deviation. Although IVL appears to be 
associated with a low incidence of overall complications based on our present findings, further evidence 
from RCTs and longer-term follow-up is required to advocate its routine use in patients with CAC. 
7. Conclusion:  
Intravascular lithotripsy can offer a significant improvement in the vessel lumen to facilitate coronary 
stent delivery and deployments in severely calcified coronary arteries. Further evidence from RCTs and 
longer-term follow-up are required to advocate its routine use in patients with CAC. 
 
Funding 
This paper was not funded 
 
Declaration of Interest 
The authors have no relevant affiliations or financial involvement with any organization or entity with a 
financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. 
This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, 

















1. Bourantas CV, Zhang YJ, Garg S, et al. Prognostic implications of coronary calcification in patients 
with obstructive coronary artery disease treated by percutaneous coronary intervention: a 
patient-level pooled analysis of 7 contemporary stent trials. Heart 2014;100(15):1158-64. 
2. Lee MS, Shah N. The Impact and Pathophysiologic Consequences of Coronary Artery Calcium 
Deposition in Percutaneous Coronary Interventions. J Invasive Cardiol 2016;28(4):160-7. 
3. Barbato E, Shlofmitz E, Milkas A et al. State of the art: evolving concepts in the treatment of 
heavily calcified and undilatable coronary stenoses - from debulking to plaque modification, a 
40-year-long journey. EuroIntervention 2017;13(6):696-705. 
4. Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of complex 
coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon 
Angioplasty Comparison (ERBAC) Study. Circulation 1997;96(1):91-8. 
5. Serruys PW, Katagiri Y, Onuma Y. Shaking and Breaking Calcified Plaque: Lithoplasty, a 
Breakthrough in Interventional Armamentarium? JACC Cardiovasc Imaging 2017;10(8):907-911. 
6. Sgueglia GA, Gioffre G, Piccioni F et al. Slender distal radial five French coronary shockwave 
lithotripsy. Catheter Cardiovasc Interv 2019;94(3):395-398. 
7. Genereux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of 
calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI 
(Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and 
ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. J Am Coll 
Cardiol 2014;63(18):1845-54. 
8. Reisman M, Shuman BJ, Dillard D et al. Analysis of low-speed rotational atherectomy for the 
reduction of platelet aggregation. Cathet Cardiovasc Diagn 1998;45(2):208-14. 
9. Brinton TJ, Ali ZA, Hill JM, et al. Feasibility of Shockwave Coronary Intravascular Lithotripsy for 
the Treatment of Calcified Coronary Stenoses. Circulation 2019;139(6):834-836. 
10. Ali ZA, Brinton TJ, Hill JM, et al. Optical Coherence Tomography Characterization of Coronary 












11. Ali ZA, Nef H, Escaned J, et al. Safety and Effectiveness of Coronary Intravascular Lithotripsy for 
Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study. Circ Cardiovasc 
Interv 2019;12(10):e008434. 
12. Aksoy A, Salazar C, Becher MU et al. Intravascular Lithotripsy in Calcified Coronary Lesions: A 
Prospective, Observational, Multicenter Registry. Circ Cardiovasc Interv 2019;12(11):e008154. 
13.       Ielasi A, Moscarella E, Testa L, et al. IntravaScular lithotripsy for the Management of      
undILatable coronary stEnt: The SMILE Registry. Cardiovasc Revasc Med 2020; 1553-8389: 
https://doi.org/10.1016/j.carrev.2020.05.020 
14. Wong B, El-Jack S, Khan A et al. Treatment of Heavily Calcified Unprotected Left Main Disease 
With Lithotripsy: The First Case Series. J Invasive Cardiol 2019;31(6):E143-e147. 
 
 
List of Figures and Tables 
Table 1: Showing baseline demographics, comorbidities, and procedural characteristics of the study 
population.  
Table 2: The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-
analyze 






































































































































































– 2M7380) 60408030% (n) 80) 1513y  (n) 23, (n) 60S-IVL - mm) 4.(pre-IVL / 4 
(French 6 
ographics, c
SRUPT CAD I B
017 9 ulti-national (5 c ± 7  (48)   (24)  (48)  (18)  (48)  (9)  (8) 
 (14) - CABG 
 
0 x 12 
atm / 6 atm 
F 
omorbiditie




– 2017 10 Multi-national71 ± 10 80 (25) 31 42 (13) 24 (77) 7 (23) 26 (83) 7 (23) - 
- 










2019 11 Multi-nationa72 ± 1078 (94) 120 26 (31) 80 (96) 32 (38)72 (86)13 (16)3 (4) 
7 (8) CABG 
120 10 4.0 x 12 
4 atm / 6 atm
6 F 
ation.  




2019 12 Germany76 ± 1051 (72) 71 45 (32) 93 (66) 34 (24)62 (45)37 (26)17 (12) 
3 (4) 
- - 4.0 x 12 














No. of stent pass 100% (60) 100% (31) 100% (120) - Approach - Transradial or Transfemoral - - Left main Stem Blockage % (n) 2 (1) 0 0.8 (n=1) 17 (13) LAD Blockage 47 (28) 14 (45) 63 (75) 44 (34) LCX Blockage 13 (8) 5 (16) 12 (14) - Diagonal branch (DI) blockage - 0 25.0 (30) - Follow up 6 months 1d 30 days 30 days 
 
            
 
Table 2. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis
Selection Outcome 
Study Representativeness of the exposed cohort Selection of the non-exposed cohort Ascertainment of exposure Outcome not present at baseline Comparability of the cohort 
Assessment of outcome 
Enough follow- up duration 
Adequate follow- up Total score 
















Supplementary file 1 
 
Search Strategy  
MeSH +Keyword: Intravascular shockwave lithotripsy Shockwave intravascular lithotripsy Coronary lithotripsy IVL S-IVL Acute coronary syndrome ST-elevation myocardial infarction Non-ST elevation myocardial infarction Unstable angina Stable angina Calcified coronary artery disease Failed percutaneous coronary intervention Stent under expansion Drug eluting stent Failed rotational atherectomy 
 
PubMed  (((((Intravascular shockwave lithotripsy) OR (Shockwave intravascular lithotripsy)) OR (coronary lithotripsy)) OR (IVL)) OR (S-IVL)) AND ((((((((((Acute coronary syndrome) OR (ST-elevation myocardial infarction)) OR (Non-ST elevation myocardial infarction)) OR (Unstable angina)) OR (Stable angina)) OR (Calcified coronary artery disease)) OR (Failed percutaneous coronary intervention)) OR (Stent under expansion)) OR (Drug eluting stent)) OR (Failed rotational atherectomy))   
Embase Classic+ Embase 1947 (inception) to 2020 October 08 
# Searches Results 1 exp lithotripsy/ 14948 











2 coronary lithotripsy.kw. 3 3 Intravascular shockwave lithotripsy.tw. 2 4 Intravascular lithotripsy.kw. 28 5 Shockwave lithotripsy.kw. 428 6 S-IVL.mp. 49 7 IVL.tw. 927 8 IVL.kw. 219 exp acute coronary syndrome/ or exp coronary artery disease/ or exp ischemic heart disease/ or exp non st segment elevation acute coronary syndrome/ 854559 10 calcified coronary artery disease.mp. or coronary artery calcification/ 5440 11 exp st segment elevation myocardial infarction/ or exp heart infarction/ 409023 12 exp non ST segment elevation myocardial infarction/ 15192 13 exp unstable angina pectoris/ 24390 14 exp stable angina pectoris/ 1153915 Failed percutaneous coronary intervention.kw. 0 16 exp percutaneous coronary intervention/ or exp interventional cardiovascular procedure/ or exp transluminal coronary angioplasty/ 148096 
17 
exp drug eluting stent/ or exp stent/ or exp sustained release preparation/ or exp drug eluting cardiovascular stent/ or exp drug eluting digestive stent/ or exp drug eluting nitinol stent/ or exp drug eluting sinus stent/ or exp drug eluting tracheobronchial stent/ or exp drug eluting ureter stent/ or exp drug eluting urethral stent/ 
203824 




Cochrane Central Database: Date Run: 10/10/2020 00:26:53 











1 Intravascular shockwave lithotripsy 6 2 Shockwave intravascular lithotripsy 6 3 Coronary lithotripsy 14 4 IVL 39 5 S IVL 14 6 Intravasc* Lithotri* 11 7 Acute coronary syndrome 67918 ST-elevation myocardial infarction 3121 9 Non-ST elevation myocardial infarction 1616 10 Unstable angina 4286 11 Calcified coronary artery disease 198 12 percutaneous coronary intervention 10,644 13 Stent under expansion  48 14 Drug eluting stent 394115 atherectomy 462 16 #1 OR #2 OR #3 OR #4 OR #5 OR #6 53 17 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 21449 18 #16 AND #17 13 
  ClinicalTrials.gov  search map: 
Terms Search Results* Entire Database**Synonyms 
lithotripsy 9 studies 180 studiesLitholapaxies -- 1 studies
calcified coronary artery disease -- 1 studies











Terms Search Results* Entire Database**Synonyms cardiac ischaemia -- 28 studiesCoronary Arterioscleroses -- 149 studiescoronary artery atherosclerosis -- 3 studiescoronary atheroma -- 7 studiesCoronary Atheroscleroses -- 136 studiescoronary heart disease -- 705 studiesDisease coronary artery -- 1 studiesischaemic heart disease -- 433 studies
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